Nurix Therapeutics, Inc. (NRIX)
NASDAQ: NRIX · Real-Time Price · USD
22.64
-0.15 (-0.66%)
Nov 20, 2024, 4:00 PM EST - Market closed
Nurix Therapeutics Employees
Nurix Therapeutics had 284 employees as of November 30, 2023. The number of employees decreased by 13 or -4.38% compared to the previous year.
Employees
284
Change (1Y)
-13
Growth (1Y)
-4.38%
Revenue / Employee
$198,676
Profits / Employee
-$623,155
Market Cap
1.60B
Employees Chart
Employees History
Date | Employees | Change | Growth |
---|---|---|---|
Nov 30, 2023 | 284 | -13 | -4.38% |
Nov 30, 2022 | 297 | 55 | 22.73% |
Nov 30, 2021 | 242 | 107 | 79.26% |
Nov 30, 2020 | 135 | 42 | 45.16% |
Nov 30, 2019 | 93 | - | - |
Related Stocks
Company Name | Employees |
---|---|
Teladoc Health | 5,600 |
Certara | 1,391 |
10x Genomics | 1,259 |
InMode | 581 |
Immunocore Holdings | 497 |
Arvinas | 445 |
Dynavax Technologies | 408 |
Travere Therapeutics | 380 |
NRIX News
- 15 hours ago - Nurix Therapeutics Receives PRIME Designation from the European Medicines Agency for NX-5948 for the Treatment of Relapsed or Refractory Chronic Lymphocytic Leukemia - GlobeNewsWire
- 3 days ago - Nurix Therapeutics Presents Preclinical Data from Two Autoimmune and Inflammatory Disease Programs, NX-5948 and GS-6791, at ACR Convergence 2024 - GlobeNewsWire
- 21 days ago - Nurix Therapeutics to Participate in Upcoming Investor Conferences - GlobeNewsWire
- 4 weeks ago - Nurix Therapeutics Announces Presentations at the 7th Annual TPD & Induced Proximity Summit - GlobeNewsWire
- 4 weeks ago - Nurix Therapeutics Presents Positive Results from the Ongoing Clinical Trial of Its BTK Degrader NX-5948 in Patients with Relapsed/Refractory Waldenstrom's Macroglobulinemia - GlobeNewsWire
- 5 weeks ago - Nurix Therapeutics Expands Its Board of Directors with the Addition of Drug Commercialization Expert Anil Kapur - GlobeNewsWire
- 5 weeks ago - Nurix Therapeutics Reports Third Quarter Fiscal 2024 Financial Results and Provides a Corporate Update - GlobeNewsWire
- 6 weeks ago - Nurix Therapeutics Announces Presentations at ACR Convergence 2024, the Annual Meeting of the American College of Rheumatology - GlobeNewsWire